[1. Field-Smith A, Morgan GJ, Davies FE. Bortezomib (Velcade™) in the treatment of multiple myeloma, Ther and Clin Risk Manag. 2006; 2:271-9.]Search in Google Scholar
[2. Romaniuk W, Ołdziej AE, Zińczuk J, Kłoczko J. Proteasome inhibitors in cancer therapy. Postepy Hig Med Dosw. 2015;69: 1443-50.]Search in Google Scholar
[3. Carvalho C, Santos RX, Cardoso S, Correia S, Oliveira PJ, Santos MS, Moreira PI. Doxorubicin: the good, the bad and the ugly effect. Curr Med Chem. 2009;16:3267-85.10.2174/09298670978880331219548866]Search in Google Scholar
[4. Lipchick BC, Fink EE, Nikiforov MA. Oxidative stress and proteasome inhibitors in multiple myeloma. Pharmacol Res. 2016; 105:210-5.10.1016/j.phrs.2016.01.029504486626827824]Search in Google Scholar
[5. Perez-Galan P, Roue G, Villamor N, Montserrat E, Campo E, Colomer D. The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status. Blood. 2006;107:257-64.10.1182/blood-2005-05-209116166592]Search in Google Scholar
[6. Ling YH, Liebes L, Zou Y, Perez-Soler R. Reactive Oxygen Species Generation and Mitochondrial Dysfunction in the Apoptotic Response to Bortezomib, a Novel Proteasome Inhibitor, in Human H460 Non-small Cell Lung Cancer Cells. J Biol Chem. 2003;278: 33714-23.10.1074/jbc.M30255920012821677]Search in Google Scholar
[7. Fribley A, Zeng Q, Wang CY. Proteasome inhibitor PS-341 induces apoptosis through induction of endoplasmic reticulum stress-reactive oxygen species in head and neck squamous cell carcinoma cells. Mol Cell Biol. 2004;24:9695-704.10.1128/MCB.24.22.9695-9704.200452547415509775]Search in Google Scholar
[8. Ning YM, He K, Dagher R, Sridhara R, Farrell AT, Justice R et al. Liposomal doxorubicin in combination with bortezomib for relapsed or refractory multiple myeloma. Oncology. 2007;21:1503-8.]Search in Google Scholar
[9. Kumar SK, Callander NS, Alsina M, Atanackovic D, Biermann JS, Chandler JC et al. Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017;15:230-69.10.6004/jnccn.2017.002328188192]Search in Google Scholar
[10. https://clinicaltrials.gov/ct2/results?cond=&term=bortezomib%2C+doxorubicin&cntry=&state=&city=&dist= open access: 01.09.2018]Search in Google Scholar
[11. Terwilliger T, Abdul-Hay M. Acute lymphoblastic leukemia: a comprehensive review and 2017 update. Blood Cancer Journal. 2017;7:e577.10.1038/bcj.2017.53552040028665419]Search in Google Scholar
[12. ClinicalTrials.gov Identifier: NCT00440726]Search in Google Scholar
[13. https://clinicaltrials.gov/ct2/show/NCT00440726?term=bortezomib%2C+doxorubicin&cond=ALL%2C+Childhood&rank=1 open access: 01.09.2018]Search in Google Scholar
[14. Shah JJ, Orlowski RZ, Thomas SK. Role of combination bortezomib and pegylated liposomal doxorubicin in the management of relapsed and/or refractory multiple myeloma. Ther and Clin Risk Manag. 2009;5:151-9.]Search in Google Scholar
[15. Horton TM, Gannavarapu A, Blaney SM, D’Argenio DZ, Plon SE, Berg SL. Bortezomib interactions with chemotherapy agents in acute leukemia in vitro. Cancer Chemother Pharmacol. 2006;58:13-23.10.1007/s00280-005-0135-z16292537]Search in Google Scholar
[16. Irimia R, Tofolean IT, Sandu RG, Băran OE, Ceauşescu MC, Coşoreanu V et al. Quercetin, Menadione, Doxorubicin combination as a potential alternative to Doxorubicin monotherapy of acute lymphoblastic leukemia. Documenta Haematologica. 2015;24.10.1515/dch-2015-0005]Search in Google Scholar